Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Why is it when we provide evidence that you are incorrect you change your story? Why don’t you find me a drug that was denied approval because of a SAP change that was done prior to unblinding? Prove to me that could be the basis of a denial.
“Certain optimization work will be required so that the Flaskworks system will produce DCVax-L products with characteristics equivalent to the products made by the current DCVax-L manufacturing processes. This will then need to be confirmed by comparability studies.”
That is a direct quote from the company. Further clinical studies are NOT needed.
Again, you are wrong. Look here. These were updated in October 2020 in the EU. It was submitted PRIOR to data lock in October 2020.
https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001977-13/GB#summary
They don’t have much of a choice right now. They’ll continue to dilute at any level to keep the lights on. There should be no concern about that. If there was a large offering at these prices, that would be a red flag.
There is definitely an interest for Merck. That’s about 2 billion in revenue for each Merck and NWBO with this combo. The thought that big pharma doesn’t want DCVax Goes out the window since it makes their drugs better.
Can you explain how the data was dredged “post hoc” when they were still blinded? How do you dredge data that hasn’t been seen?
They could have burned $100 billion for all I care. What does it matter? You don’t have to pay back that money. You invest at these levels and reap the benefits when this gets approved. If the approval takes 50 years and you invest at year 49, do you really care what happened in the previous 49 years? It is irrelevant.
I would be happy to be a meme stock. Without retail, AMC would have had to file bankruptcy. AMC was able to dilute at higher prices to ensure its survival. If retail got behind this and pushed the stock to $10 by the end of the year, the Company could easily raise $500 million. Things move much quicker when money is not an issue. It also puts the Company in a much stronger negotiating position when it’s sitting on solid financial ground with 3rd parties. At this point, the only valid knock on the Company is it’s cash poor. With some help from retail, we could begin 2023 with enough money to start direct trials on our own.
At this point, buyout is highly unlikely and unnecessary. Phase 3 data for DCVax-L is in and the company has stated they are making preparations for applications. Manufacturing is set. A large sales staff is not needed. There is no need for BP to be involved for DCVax-L.
However, I do see a partnership occurring for Direct and/or Prostate. The new guidance from the FDA regarding oncology drugs is huge. This change didn’t happen overnight and I believe pharma companies know what changes the FDA is making before it becomes official policy. This development will dramatically lower the cost for bringing Direct to market for multiple indications. Lower development costs with a larger potential market means the price of partnering has gone up.
In my opinion, a partnership will happen in 2023 with a BO occurring a few years down the line.
Someone posted information about Milken and Dendreon earlier and I decided to read a little bit more about it. I found this article: https://www.sec.gov/comments/s7-08-09/s70809-4614.pdf
After reading through it, a lot of what happened to Dendreon is what you see with NWBO. In particular, you see how these posters continue to claim the trial was a failure when it clearly wasn’t. I honestly thought these people couldn’t understand trial results. After reading that article, it make sense now that these people purposely sow doubt when it’s clear a trial was successful. The article is interesting and even Dr. Padzur is mentioned. Looks like NWBO is avoiding the same issues that hurt Dendreon.
Unfortunately you can’t buy NWBO on Robinhood. I’m sure a lot of the Reddit crowd can’t buy in since they use Robinhood.
I agree that causation may become the issue. However, under 10b-5, even an unsuccessful attempt at spoofing without successful price manipulation would be actionable. This would severely impact the damages but would still trigger the attorney fees provision.
The lack of posts complaining about them.
Interesting to see the calls for new management have seemed to stop in 1 day.
I’ll say it for you: he’s wrong. The opposite is true. If the share price is low, it costs the company more in shares not less. It costs the company more to pays its executives. The Company is the plaintiff not LP. If LP somehow benefited, then it shows the Company was hurt by it.
This probably would not go to trial. 90%+ of civil cases settle. Since these spoofs trades are recorded events, there will not be much in the way of factual disputes. Either the trades were put in or they weren’t. From a strategic point of view, I wouldn’t be surprised to see them bifurcate liability and damages. It would set up nicely for summary judgment that way. Of course, we wouldn’t see this all play out for at least a couple years.
Civil Rico wouldn’t be good in this case because you would have to show the defendants were all part of one big scheme. For example, defendant x put the sell order in and defendant y put the buy order in and together it would force the price down. Needs to have some coordination. It sounds like each defendant was doing this on their own independent of the other defendants.
I completely agree. One would think of dropping this lawsuit prior to the JAMA article to end the manipulation. I think there’s another drop of news coming soon.
No I believe that to case but what I believe and what you can prove are 2 separate things. If you’re arguing that these companies were the source of the decline, you would have to prove it AND prove the amount of damages. It would be extremely difficult requiring experts. The other side would provide experts saying that is not the case. Remember that the plaintiff has the burden of proving its case. If I was defending that case, I would argue other bad actors like AF were the cause of the decline. The best thing the Company can do is go with the slam dunk win. The bigger thing is it may stop the manipulation.
From a legal point of view, the Company needs to show a tangible loss. The best way I can explain it is this: a stock is worth $1 on Monday. Stock gets manipulated down to .50 on Tuesday. By Friday, stock is back at $1. If you never sold at the lower price, you have no concrete damages. You can always argue that the stock should have been higher than $1 at that point but damages become speculative and almost impossible to prove.
Yes I can. Give me about 30 min.
There’s always a chance. It would have to get the attention of the Feds and would probably be further down the line time wise. The JP Morgan case resulted in convictions but that was also much larger.
Laura H. Posner
Michael B. Eisenkraft
Jessica (Ji Eun) Kim
COHEN MILSTEIN SELLERS & TOLLPLLC
You don’t file federal cases without having the evidence to win. It’s that simple. The risk of sanctions are too high. These allegations are not done on information and belief and are pled with specificity.
This lawsuit won’t cost the company anything. There are attorney fees as damages. These firms typically take the cases on contingency.
The Dodd Frank act outlawed spoofing. This is not business as usual. It is illegal manipulation.
The settlement will stay with the company. I expect a class action will eventually be commenced for individual shareholders who sold stock.
It came from loan and dilutions. You make it seem like it’s a foregone conclusion that they are issuing 500 million shares imminently at these prices. The C shares are equivalent to 250 million of those shares and the equivalent of less than 25 million were issued based on the last 10Q. Does management want to dilute at lower prices? No. You thinking that a PR blitz causing a huge raise in SP is also short sighted. This is not Tesla and LP is not Elon. You will not get the same reaction.
Oh really? Can you show me the offering with 500 million shares? Or do you not understand what authorized shares mean?
Maybe you should look at the financials and see that the company has no money. Why would they waste money on a PR storm now? So this can go up a couple bucks and you can sell? The company is working towards approval. They should allocate their money there. Approval, sales, revenue and the share price will take care of itself.
I hope you’re right but it’s doubtful. The PR with the results said they were still working on preparations for applications for regulatory approvals. Sounds like they’re not working on the actual applications yet. Maybe some prerequisites for applications?
The posts calling for new management are crazier than the imminent $30 billion buyouts. Management is not going anywhere anytime soon. Yes they’re older. The president is 80. Iger came back to Disney at 71. No reason management won’t stick around another 2 years to get maximum value. Those who doubt the share price manipulation need to review the 5/10 debacle. Shares were cratering even before the positive news dropped. Rather than complaining about the SP, take advantage. I have 11 times the shares I owned in 2021. This is a rare gift from the market. I’ll continue to accumulate and will be rewarded in 2023. This is as close to a guaranteed approval I’ve ever seen.
Random thoughts as I feel how this stock plays out:
No news other than manufacturing before ASM
NWBO submits and gets approvals for DCVax-L alone in 2023
Partnership occurs in 2023 for Prostate and/or Direct only
Share price ends the year at a little over $1
Early 2023, share price starts to rise for what seems like no reason at all as manipulation come to an end
Uplisting in mid 2023 before approvals
No buyout until 2024 at the earliest
Share price $8-$12 end of 2023
It also hit 21 billion MC at its peak. Revenue of 550 million a year. NWBO should blow it out of the water.
They could sue but they still have to prove damages. In some cases, damages are presumed but they could be nominal. Damages to MC would not be recoverable. The company hasn’t suffered harm, investors have. The argument would have to be the company diluted at a lower price after the defamatory statement and that would be the damage. Again, this is all speculative because the company would have to show the article was responsible. It’s an extremely tough case to litigate.
I misunderstood your response. I completely agree with you.
Hey genius. Read that PR. It has exactly what you want it to say. You want them to add, in response to all the criticism, read this again? FYI Jared ate the sandwiches, he didn’t make them. Even your insults don’t make any sense.
So you want them to reissue the November 17 press release? Great solution. That would solve everything. I wish you were running this company.
The company doesn’t have any control over any type of criminal prosecution of AF. The best they could do is report him to the SEC to see if a crime has been committed. Unless he’s part of a short selling ring or selling short himself, AF has not committed any crime. From a civil perspective, it would be almost impossible to prove that AF was responsible for anything. If you remember on 5/10, the stock was dropping before results and before the AF hit piece. This time, the price was pulling back even before AF issued his story. The law requires a plaintiff to prove damages. It’s not as easy as this board make it seem. Unless a law firm take it on contingency, I would rather have the company spend its money on gaining approvals.